Share

Contacts

  • BioGaia AB
    Kungsbroplan 3A, 103 64 Stockholm
    +46 (0)8 555 293 00
    http://www.biogaia.com
  • Quotes

    Up to 50 percent of older women are affected by fractures. The fact that Lactobacillus reuteri ATCC PTA 6475 was shown to reduce bone loss in this group is therefore very promising. We hope that further studies will confirm the results, so that this new way of maintaining good bone health in old age can be of use.
    Axel Sjöblad, Managing Director, BioGaia
    We announced the results of this study already in October 2015 but now have the opportunity to highlight them again. The fact that L. reuteri Protectis may mitigate terrible consequences of diarrheal disease, like stunting, cognitive deficiencies and eventual adult accomplishments, and contribute to decrease in recurrent diarrhea, increased growth and improved quality of life for children in sub-Saharan countries is very encouraging.
    Axel Sjöblad, Managing Director, BioGaia
    Sales in the second quarter of 2017 reached SEK 156 million, which is an increase of 15% compared to the same period of last year. The strong second quarter, when sales to our important market Brazil gained new momentum, meant that for the first six months we achieved sales of SEK 297 million, a gross margin of 75% and an operating profit of SEK 115 million. We are on the right track and continue with the implementation of our strategic initiatives. I am also very pleased that in the quarter we established the subsidiary BioGaia Pharma AB to take advantage of the opportunities to develop drugs identified in the R&D activities conducted as part of our core business.
    Axel Sjöblad, Managing Director of BioGaia AB
    Sales during the first quarter of 2017 amounted to SEK 141 million, which was an increase of 5% compared to the corresponding period last year. This in combination with a strong gross margin meant that the operating profit reached SEK 56 million and increased by 9%. After the strong end of 2016, some countries had a slower sales start in 2017. Therefore, it was gratifying that we could compensate for this through revenues linked to the new agreements signed in December 2016 with Kabaya Ohayo Holding in Japan and continued growing royalty revenues by Nestlé.
    Axel Sjöblad, Managing Director of BioGaia AB
    We have a very strong focus on developing our oral health business and our sales of Prodentis, for which we have strong clinical evidence. I am therefore very happy that we have signed another three agreements with solid partners in both Canada and Asia.
    Axel Sjöblad, Managing Director, BioGaia
    I am very happy that we have signed this exclusive agreement which further confirms the fruitful collaboration we have with Nestlé. The Australian launch of our Protectis drops, which fits perfectly with Nestlé’s offering, is a great opportunity for us to broaden BioGaia’s reach in the Asia Pacific region.
    Axel Sjöblad, Managing Director, BioGaia
    Looking back at 2016, we can only feel satisfied. With sales growth of 9% excluding foreign exchange effects, we were able to pass the half billion mark and achieve annual sales of SEK 534.7 million. This enabled us to increase our market shares despite the fact that the sales to Brazil, one of our most important markets, were low as a result of the inventory build-up during 2015. The operating profit, excluding the distributed former subsidiary IBT, reached SEK 199.4 million, an increase of 14% excluding foreign exchange effects, which leads to an operating margin of 37%. Our strong financial development, while we were building a platform for future growth and signing new distribution agreements in Japan and Thailand, demonstrates the strength of our business model, our employees and our products, and gives us reason to look to the future with continued confidence.
    Axel Sjöblad, Managing Director of BioGaia AB
    We have a strong focus on growing our Asian business and I am very pleased that BioGaia’s products will be available in another important country in the region. Based on the positive experience we already have in collaborating with Abbott in Latin America, I look forward to a successful launch of our products with Abbott in Thailand as well
    Axel Sjöblad, Managing Director, BioGaia.
    “Through these two milestone agreements with Nippon Kabaya Ohayo Holdings Inc. we have secured another trusted partner in the complex Japanese market. In addition to the marketing and sales of our supplements we look forward to the creation of innovative functional foods based on our Lactobacillus reuteri strains”
    Axel Sjöblad, Managing Director BioGaia
    Third quarter sales were driven by strong growth in Asia and Europe, where the launch of EasyDropper is continuing. Net sales for the first nine months reached SEK 395.9 million. It is highly gratifying that we have now passed the level for 2015, in spite of the major inventory build-up in Brazil last year. Promising is also the trend in Business Unit Adult Health, which has shown growth for two consecutive quarters. I would also like to mention that the clinical study on reduction of pregnancy gingivitis, which we have previously reported on, has been very well received by our partners, and it is very satisfying that we have signed a sales agreement in Western and Eastern Africa
    Axel Sjöblad, Managing Director of BioGaia AB
    I am very happy that we have signed an agreement that gives BioGaia access to Central and Eastern Africa, a market with large potential for our products. Phillips Pharma Group is a strong and reliable partner with local presence in several important markets and I look forward to a fruitful collaboration.
    Axel Sjöblad, Managing Director, BioGaia
    Net sales in the first half of 2016 reached SEK 269.9 million and it is very satisfying that we have reached the same level as in the same period of 2015 despite the large inventory build-up in Brazil in 2015. Second quarter earnings were driven by very strong sales in Europe where the Easy Dropper launch continues, strong sales in Asia and modest sales in the USA and Canada. With regard to the USA and Canada it is important to note that cumulative sales for January to June 2016 rose by 21% compared to the same period of last year. Furthermore, I would like to highlight the solid development in the Business Unit Adult Health which grew by 15 % compared to second quarter last year, partly driven by the continued roll-out of ProDentis and Gastrus. Finally, two new clinical studies, one on treatment of abdominal pain in children and the other on reduction of gingivitis in pregnant women (a new target group for us), have further demonstrated the strength of our products.
    Axel Sjöblad, Managing Director of BioGaia AB
    Our study shows that L. reuteri containing lozenges may be a valuable adjunct in the control of pregnancy gingivitis
    Professor Ulrich Schlagenhauf
    Stomach pain is common among children and often affects the child’s daily life through for example anxiety and school absenteeism. It is therefore very gratifying that this study, which confirms earlier results with L. reuteri Protectis, shows that BioGaia ProTectis could offer these children an effective, safe and easy option.
    Axel Sjöblad, Managing Director, BioGaia
    Compared to the same period of last year, the first quarter of 2016 showed a varied palette of sales successes in Canada and the USA, modest development in Europe and declining sales in Asia and Rest of World. The highlights included the successful launch of our new Easy Dropper, which will eventually replace the glass bottles for our drops, and two meta-analyses that confirm the effectiveness of BioGaia ProTectis in colic and the effectiveness of BioGaia ProDentis in periodontitis. At the end of the period we distributed the shares in IBT to our shareholders, and since that time IBT is an independent company that is listed on Nasdaq First North.
    Axel Sjöblad, Managing Director of BioGaia AB
    A meta-analysis is considered the highest level of evidence of a health effect and now there are eight such meta-analyses with BioGaia ProTectis. While this clearly confirms BioGaia ProTectis as the number one treatment for infants with colic, it also reassures health care professionals around the world that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients.
    Axel Sjöblad, Managing Director, BioGaia
    BioGaia ProDentis as an adjunct in the management of patients with implants is a promising new indication. With BioWellTech we have a strong and experienced local partner within this area and we therefore hope for a successful launch of BioGaia ProDentis in Hong Kong.
    Axel Sjöblad, Managing Director, BioGaia
    The meta-analysis confirms BioGaia ProDentis' unique position as the only clinically proven probiotic for patients with chronic periodontitis. Today dental professionals around the world can be reassured that they are suggesting an effective treatment when recommending BioGaia ProDentis as an adjuvant to standard treatment to their patients. It is also encouraging that the authors suggest that L. reuteri may be used to reduce the use of systemic antibiotics and by that, potentially, lowering the risk for antibiotic resistance.
    Axel Sjöblad, Managing Director, BioGaia
    We cannot but feel happy and satisfied with the past year. Thanks to sales growth of 16% after exchange rate adjustments, we are now approaching sales of one half billion. According to our data, the total market for probiotic dietary supplements is expanding by around 8% annually, which means that we are winning market shares. Our operating profit reached SEK 152 million, resulting in an operating margin of over 31%. And this was achieved despite expenses of SEK 20.6 million for our subsidiary IBT. Without these expenses our operating margin would have been a full 36%.
    Peter Rothschild, Managing Director BioGaia
    The new meta-analysis once again confirms our position as the number one treatment for infants with colic. Today health care professionals around the world can be totally reassured that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients.
    Peter Rothschild, President, BioGaia
    We are very happy to see that IBT has reached these important milestones. This confirms that IBT:s drug development to date meets the requirements of both agencies to begin clinical trials in premature infants, the most vulnerable of all humans.
    Peter Rothschild, President, BioGaia and Chairman of the IBT board
    We are now able to conduct clinical trials both in the US and in an EU country and we are naturally excited to move on with our drug development with the aim of satisfying the global need to find a preventive therapy for NEC.
    Staffan Strömberg, President, Infant Bacterial Therapeutics
    Asia is a market with great potential and I am pleased that BioGaia’s products will be available in yet another country here. With the reputable local partner Axero we hope for a successful launch of our key products in Sri Lanka
    Peter Rothschild, President, BioGaia
    I am pleased to say that sales and profit for the third quarter were highly satisfactory. In the past 12-month period sales were up by 41%, or 30% excluding foreign exchange effects
    Peter Rothschild, president BioGaia AB
    Axel Sjöblad has extensive experience of and an impressive track record in the healthcare and life sciences area through his earlier positions in the Gambro and Getinge groups. The Board is confident that Axel Sjöblad is well suited to take over as Managing Director of BioGaia’s business, which Peter Rothschild has so brilliantly built up during his time at the helm. We are delighted that Peter Rothschild will continue in a key position for the company’s development
    David Dangoor, Board Chairman
    In Botswana, as well as other sub-Saharan countries, long periods of diarrhoea not only causes death but also leads to stunting and cognitive impairments. The results from this pilot study are therefore very encouraging as they indicate that our L. reuteri Protectis could contribute, both in the short as well as in the long perspective, to a better quality of life in these exposed children
    Peter Rothschild, President, BioGaia
    Another highly satisfactory quarter. After three quarters each showing a steep rise in sales, the effect over 12 month figures is obviously positive – sales have risen by 40% over the past 12 months. Both the euro and dollar have become much stronger, but even after adjustment for foreign exchange effects, our sales growth amounts to 30%, which under any circumstances deserves to be considered as satisfactory. Developments on most markets remain positive, with the strongest performances being reported from South America, especially in Brazil where our drops and tablets have been very well received.
    Peter Rothschild, President of BioGaia AB
    As Candida affects a large number of our elderly population the new and positive results could make BioGaia’s oral health probiotic ProDentis an attractive alternative to conventional antifungal drugs
    Peter Rothschild, President, BioGaia
    First-quarter sales rose by 49%, or by 37% after adjustment for foreign exchange effects. While the figures for the quarter are, obviously, satisfactory, a rolling 12-month review gives a far better picture. Also this, shows impressive rates of growth: 23% growth in sales and 19% growth in operating profit, both of these figures after adjustment for foreign exchange effects. The background to these strong results is continued success in all our key markets, with the sole exception of war-torn Ukraine. The strongest engine for growth is our Paediatrics business unit, but sales of our Adult Health products are also starting to pick up again after a few less satisfactory quarters.
    Peter Rothschild, CEO BioGaia AB
    With this study – the fifth independent, positive study with Lactobacillus reuteri Protectis on colic – we further strengthen our position in the paediatric field. Furthermore, it is valuable that we now also have strong data in this field from a study conducted in China
    Peter Rothschild, President, BioGaia
    With this additional limited funding from BioGaia we gain valuable time and thereby increasing the value of the project.
    Peter Rothschild, President, BioGaia
    Mexico is the country with the sixth highest number of diabetics in the world and diabetes is often associated with oral diseases. With a strong local partner we hope for a successful launch of BioGaia’s oral health products in Mexico
    Peter Rothschild, President, BioGaia
    Ten years ago peri-implantitis was a condition that hardly existed. Today it is on the rise and a major concern given the increasing number of patients with dental implants. This study shows that Lactobacillus reuteri Prodentis is effective in both the treatment and prevention of dental implant diseases and will support the growth of BioGaia’s business in dental clinics around the world.
    Peter Rothschild, President, BioGaia
    We are pleased that the European Commission have granted the Orphan Drug Designation. We are confident that our subsidiary IBT can significantly contribute in the care of premature infants in the future
    Peter Rothschild, CEO, BioGaia
    A sales growth of 22% (including licence revenue from Nestlé 53 %) and an operating margin of 26%¹ for the full year 2014, can only be summed up as a successful year
    Peter Rothschild, CEO of BioGaia AB
    We are pleased and excited about this cooperation and look forward to working with Nestlé with the launch of the new product with L. reuteri Protectis.
    Peter Rothschild, President of BioGaia
    Asia is a market with great potential and I am pleased that BioGaia’ products will be available in yet another country here. With the reputable local partner VietPhap we hope for a successful launch of our paediatric portfolio in Vietnam.
    Peter Rothschild, President, BioGaia
    Constipation is a common problem world wide and many of the current treatment options have side effects. Lactobacillus reuteri Protectis has already been shown to be an effective alternative in children and it is satisfying that the new results confirm that this also applies to adults with constipation.
    Peter Rothschild, President, BioGaia
    I am very pleased that we are deepening our interesting collaboration with Prof. Fredrik Bäckhed and now also with Prof. Jens B Nielsen and their research teams, aiming to develop the next generation of probiotic products that could be possible with the help of this new and advanced technology
    Peter Rothschild, CEO of BioGaia
    With this study – the fourth independent, positive study with Lactobacillus reuteri Protectis on colic – we further strengthen our position in the paediatric field. Furthermore, it is valuable that we now also have strong data in this field from a study conducted in North America.
    Peter Rothschild, President, BioGaia
    The strong growth in sales during the quarter is gratifying, and the rolling 12 month performance, indicating where we are going long term, shows a 19 % increase. Our ambitions are higher than that, and considering the positive signals we are seeing in essentially all markets, we should be able to reach our historically high growth numbers within a not too distant future.
    Peter Rothschild, CEO of BioGaia AB
    We have achieved strong profitability for the first half of the year with an operating margin of 29 % excluding license revenue from Nestlé. Including license revenue from Nestlé, operating margin was 53 %. Sales for the rolling 12-month period amount to 12% (excluding foreign exchange effects)
    Peter Rothschild, CEO BioGaia AB
    I am delighted that we after many years of preparations have been able to conclude a contract for this large market. We have established an important key opinion leader network in the UK and the drops are already sold in a few hospital pharmacies. Considering SMA’s market position and our preparatory work I am convinced that sales will expand quickly.
    Peter Rothschild, President, BioGaia
    For a long time we have tried to find a suitable way to enter the large Indian market. Through the agreement with Pharma Base we have access to a partner with extensive experience in the Indian market and with a proven track record.
    Peter Rothschild, President, BioGaia
    The quarter saw a 60 % increase in operating profit and for the past 12-month period a 45 % increase. Despite only a limited growth in costs, it is still possible for sales to rise significantly, which shows that our business model is working well. Over and above the 60 per cent increase of operating profit, a licence revenue of SEK 95.4 million from Nestlé was added during the quarter
    Peter Rothschild, CEO of BioGaia
    Our study confirms earlier published data in proving that preventive use of L. reuteri Protectis in healthy children reduces diarrhoeic episodes. Moreover, the study demonstrated a reduction of respiratory tract infections in supplemented children
    Prof. Pedro Gutiérrez-Castrellón
    We are of course very satisfied with this agreement, which gives us additional financial resources, improved profits and a great opportunity for us to develop a number of interesting products for Nestlé
    Peter Rothschild, President BioGaia
    In 2013 the sales focus for new contracts was on the BRIC countries, and it is encouraging to see that we have made real progress in nearly all of these markets. 2014 will be a very exciting year as we look forward to interesting launches in markets like Brazil. We should also have a good possibility to build up our sales in the USA, a market we still assess to have great potential
    Peter Rothschild, President of BioGaia
    Unfortunately we did not see any significant differences between the groups, but given the positive pilot study and the lessons we can draw from the recently completed study, we intend to continue our work where you with the help of a change of the microbiome achieve improvements for patients with type 2 diabetes
    Peter Rothschild, President BioGaia
    This study is ground breaking as it shows that BioGaia’s product should be given to all babies from birth. Not only does it reduce suffering in babies and parents, but it also saves the families and the society costs. This study will be immensely important for the further development of BioGaia’s baby segment
    Peter Rothschild, President BioGaia
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Rss